Cargando…

Systems Level Metabolic Phenotype of Methotrexate Administration in the Context of Non-alcoholic Steatohepatitis in the Rat

Adverse drug reactions (ADRs) represent a significant clinical challenge with respect to patient morbidity and mortality. We investigated the hepatotoxicity and systems level metabolic phenotype of methotrexate (MTX) in the context of a prevalent liver disease; non-alcoholic steatohepatitis (NASH)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Kyriakides, Michael, Hardwick, Rhiannon N., Jin, Zhaosheng, Goedken, Michael J., Holmes, Elaine, Cherrington, Nathan J., Coen, Muireann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	103
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226764/ https://www.ncbi.nlm.nih.gov/pubmed/25145655 http://dx.doi.org/10.1093/toxsci/kfu160

Ejemplares similares

COVID-ECHO : description échographique des pneumonies COVID-19
por: Flament, T., et al.
Publicado: (2022)

Milk related excipients in medications: concerns with cow’s milk protein allergy
por: Figueiredo, A., et al.
Publicado: (2021)

Troubles du sommeil chez les patients hospitalisés pour Covid-19
por: Bougrida, Mohamed, et al.
Publicado: (2022)

CONTROVERSE : je dois modifier la charge thérapeutique de la SEP en période COVID-19 : vaccinations et traitements de fond – synthèse
por: Thouvenot, Eric
Publicado: (2022)

A Two-Way Interaction between Methotrexate and the Gut Microbiota of Male Sprague–Dawley Rats
por: Letertre, Marine P. M., et al.
Publicado: (2020)

Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis
por: Clarke, John D., et al.
Publicado: (2015)

Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity
por: Jilek, Joseph L., et al.
Publicado: (2021)

Causes d’hésitation ou de refus de la vaccination contre le COVID-19 dans une cohorte de rhumatisants traités par rituximab
por: Haddouche, A., et al.
Publicado: (2022)

Translation of metabolite profiling to infectious diseases
por: Coen, Muireann, et al.
Publicado: (2010)

New parameter of the second part of the P-wave predict atrial fibrillation: comparison with P-wave signal-averaged electrocardiography
por: Lee, Y, et al.
Publicado: (2023)

The relationship of plasma catestatin concentrations with the extension of left atrial fibrosis
por: Katic, J, et al.
Publicado: (2023)

Atrial fibrillation screening to prevent stroke in patients with high NT-proBNP - a post-hoc analysis of the randomized LOOP study
por: Diederichsen, S Z, et al.
Publicado: (2023)

Quantification of atrial cardiomyopathy disease severity by electroanatomic voltage mapping and cardiac magnetic resonance imaging
por: Sim, I, et al.
Publicado: (2023)

Local conduction velocities determined by non-invasive electrocardiographic imaging predict arrhythmia-free survival after pulmonary vein isolation
por: Invers-Rubio, E, et al.
Publicado: (2023)

The role of biomarkers, sleep apnea and echocardiography as predictors of atrial fibrillation in a pacemaker population
por: Santos Sanchez, A, et al.
Publicado: (2023)

Left atrial dimensions and left atrial appendage morphology: differences in paroxysmal versus persistent atrial fibrillation patients
por: Pongratz, J, et al.
Publicado: (2023)

Rigorous and long-term cardiac monitoring strategy in cryptogenic stroke or TIA patients in a tertiary care centre results in a two-fold increase in AF detection
por: Wouters, F, et al.
Publicado: (2023)

Combining atrial activation maps for the big picture of simulated atrial fibrillation mechanisms
por: Ozgul, O, et al.
Publicado: (2023)

Extended use of preprocedural data to detect expiratory airflow limitation in patients with atrial fibrillation scheduled for ablation
por: Hereijgers, M J M, et al.
Publicado: (2023)

Diagnostic accuracy of smart gadgets/wearable devices in detecting atrial fibrillation in primary prevention: a meta-analysis
por: Vetta, G, et al.
Publicado: (2023)

Active monitoring for atrial fibrillation (AMALFI): a streamlined randomised controlled trial of remote screening for subclinical atrial fibrillation
por: Wijesurendra, R, et al.
Publicado: (2023)

Comparative metabonomic analysis of hepatotoxicity induced by acetaminophen and its less toxic meta-isomer
por: Kyriakides, Michael, et al.
Publicado: (2016)

Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients
por: Marie, Solène, et al.
Publicado: (2023)

Effect of HIV infection-related factors on SVR rate in HCV treatment in HIV-infected patients
por: Kravchenko, Alexey, et al.
Publicado: (2014)

Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis
por: Marin, Veronica, et al.
Publicado: (2017)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Sub-Chronic Microcystin-LR Liver Toxicity in Preexisting Diet-Induced Nonalcoholic Steatohepatitis in Rats
por: Arman, Tarana, et al.
Publicado: (2019)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis
por: Tsukahara, Yuko, et al.
Publicado: (2022)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system
por: Kostrzewski, Tomasz, et al.
Publicado: (2021)

Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment
por: Mori, Shunsuke, et al.
Publicado: (2018)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children
por: Kordy, Kattayoun, et al.
Publicado: (2021)

Recent advances in understanding/management of non-alcoholic steatohepatitis
por: Pacana, Tommy, et al.
Publicado: (2015)

Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
por: Brar, Gurmehr, et al.
Publicado: (2019)

Endothelial dysfunction in patients with non-alcoholic steatohepatitis
por: Onal, Ibrahim Koral
Publicado: (2014)

Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis
por: Vonghia, Luisa, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2dgelj1c60rh2lr8spm86ifjed